Lung Cancer and Immunotherapy

October 8, 2021, 2:25 pm -
3:00 pm
Breakthrough treatments for longer life

Watch On Demand

Session Description

As the most common cancer worldwide, lung cancer impacts approximately 2.1 million people each year. Hope for millions is on the horizon as the lung cancer death rate in the United States has dropped dramatically over the last few years with the introduction of new treatments, including immunotherapy. Immunotherapy for lung cancer, alone or in combination with conventional treatments, can significantly improve outcomes for lung cancer patients. Join medical oncologist Dr. Patrick Forde, M.D., of Johns Hopkins Medicine, to hear about several recently approved immunotherapy options and ask your questions about how immunotherapy is advancing the treatment of lung cancer. We’ll discuss PD-L1 expression, treatment response, length of treatment, clinical trials, and more.


Patrick Forde, M.D.

Johns Hopkins Medicine

Dr. Patrick Forde is a medical oncologist at John Hopkins Medicine who treats patients with lung cancer, mesothelioma, and other thoracic cancers. He completed training in internal medicine and oncology in Ireland prior to undertaking a further fellowship at Johns Hopkins. He is currently associate professor of oncology, associate member of the Bloomberg~Kimmel Institute for Cancer Immunotherapy, and director of John Hopkins’ thoracic oncology clinical research program. Dr. Forde has led development of a clinical-translational research program focused on the immuno-oncology of upper aerodigestive malignancies and has authored publications in New England Journal of Medicine, Nature, and Cancer Discovery among more than 100 peer-reviewed publications. His research examines the role of immunotherapy for early-stage lung cancer. Dr. Forde is principal investigator for the thoracic oncology biospecimen repository at John Hopkins. He is also principal investigator of the international phase 3 registrational trials, CheckMate-816, investigating neoadjuvant chemo-immunotherapy for resectable lung cancer, and DREAM3R, a phase 3 trial of first-line chemo-immunotherapy for mesothelioma.


Oswald Peterson

Lung Cancer Veteran

In 2017, Oswald was diagnosed with stage 4 non-small cell lung cancer. His doctor told him that a newly approved PD-1 checkpoint immunotherapy was his best treatment option. He received the first infusion in February 2017 during a three-month hospital stay. Scans showed that the cancer shrank dramatically after his second infusion. He was able to put weight back on, resume work at his nonprofit, and get back to the gym. Oswald is now cancer-free and receives immunotherapy treatment every nine weeks. He is passionate about spreading the word about cancer immunotherapy research and treatment as a CRI ImmunoAdvocate.

On-Demand Now Available

We are excited to announce that videos from our 2021 Cancer Research Institute (CRI) Virtual Immunotherapy Patient Summit are now available to view on demand.

The on-demand videos can be found on each session page from the agenda.